Mumbai: Drug company Lupin Ltd said on 13 September it has won a patent litigation in the US on blood pressure drug Altace against King Pharmaceuticals and Sanofi-Aventis, paving the way for the firm to launch the drug’s generic version in the American market.
In its ruling on Tuesday, The Court of Appeals for the Federal Circuit reversed a district court decision on Ramipril (chemically known as Altace) which said Lupin had infringed the patent.
The court’s decision makes Aventis’ patent on Ramipril invalid.
“We are in the process of determining when we can enter the market. We believe that this is a land-mark decision and is strong testament of our IP capabilities,” Lupin managing director Kamal K Sharma said in a filing to the Bombay Stock Exchange.
King Pharmaceuticals markets Altace and it has sales of over $900 million in the US market. Ramipril is one of the ACE (Angiotensin-Converting Enzyme) inhibitors, which are useful for treating high blood pressure.
Lupin’s shares were trading at Rs608, up 2.39% on BSE.